Table 3b Fludarabine combination-treated patients with one or more significant change of antivirus IgG level, values at 6–12 months post-therapy compared with baseline

From: Virus reactivations and serology patterns following first-line therapy with alemtuzumab or fludarabine-based combination therapy in patients with chronic lymphocytic leukemia

Patient

Fludarabine combination (n=17)a

 

CMV IgG

VZV IgG

Measles IgG

EBV p107 IgG

EBV VCA IgG

C3b

0

0

0

0

+

C11

0

0

0

0

−

C17

0

0

0

0

−

C18

−

0

0

0

0

Total

1 decrease

0

0

0

2 decrease

     

1 increase

  1. Abbreviations: CMV, cytomegalovirus; EBV, Epstein-Barr virus; IgG, immunoglobulin G; VZV, varicella zoster virus; 0, no significant change; −, significant decrease; +, significant increase.
  2. aNine of the totally 27 patients were not analyzed because of short follow-up (<6 months). One patient (C13) was excluded because of alemtzumab-treatment before the +12 month sample.
  3. bC3=second-line patient (FC), all the others first-line patients.
  4. All patients responded to fludarabine combination treatment.
Back to article page